Cargando…
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment
Ovarian cancer is a histologically, clinically, and molecularly diverse disease with a five-year survival rate of less than 30%. It has been estimated that approximately 21,980 new cases of epithelial ovarian cancer will be diagnosed and 14,270 deaths will occur in the United States in 2015, making...
Autores principales: | Yeung, Tsz-Lun, Leung, Cecilia S., Li, Fuhai, Wong, Stephen T. C., Mok, Samuel C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808797/ https://www.ncbi.nlm.nih.gov/pubmed/26751490 http://dx.doi.org/10.3390/biom6010003 |
Ejemplares similares
-
Systematic Identification of Druggable Epithelial–Stromal Crosstalk Signaling Networks in Ovarian Cancer
por: Yeung, Tsz-Lun, et al.
Publicado: (2018) -
ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells
por: Yeung, Tsz-Lun, et al.
Publicado: (2017) -
Calcium Dependent FAK/CREB/TNNC1 Signaling Mediates the Effect of Stromal MFAP5 on Ovarian Cancer Metastatic Potential
por: Leung, Cecilia S., et al.
Publicado: (2014) -
ISG15 Promotes ERK1 ISGylation, CD8+ T Cell Activation and Suppresses Ovarian Cancer Progression
por: Yeung, Tsz-Lun, et al.
Publicado: (2018) -
Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1
por: Au Yeung, Chi Lam, et al.
Publicado: (2016)